Drug Profile
Research programme: coronary heart disease - Myriad Pharmaceuticals/Novartis
Alternative Names: CHD1 gene; Coronary heart disease research programme - Myriad Genetics/Novartis; ZNF 202 geneLatest Information Update: 10 Aug 2007
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals; Novartis
- Developer Myriad Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Hyperlipidaemia
Most Recent Events
- 10 Aug 2007 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 10 Aug 2007 Discontinued - Preclinical for Hyperlipidaemia in USA (unspecified route)
- 04 Mar 2003 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)